An orally bioavailable Chkl inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation
Radhika Patel, Holly E Barker, Joan Kyula, Martin McLaughlin, Magnus T Dillon, Ulrike Schick, Hind Hafsi, Alan Thompson, Vincent Khoo, Kevin Harrington, Shane Zaidi
Radiotherapy and Oncology | ELSEVIER IRELAND LTD | Published : 2017
Awarded by CRUK
Awarded by Cancer Research UK
Awarded by National Institute for Health Research
Awarded by Rosetrees Trust
KJH received support from the ICR/RM NIHR Biomedical Research Centre, the Oracle Cancer Trust, The Rosetree Trust and The Anthony Long Trust. KJH, HB, MTD acknowledge research funding from CRUK (C7224/A13407). RP received funding from the Department of Urology, the Royal Marsden Hospital, London and a generous research donation from Lord and Lady Colin Marshall of Knightsbridge. We would like to thank Ian Collins, Michelle Garrett and Tom Matthews for providing CCT244747.